3-11017224-G-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 1P and 7B. PP2BP4_ModerateBP6BS2
The NM_003042.4(SLC6A1):c.13G>A(p.Gly5Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000112 in 1,613,614 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000046 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000075 ( 0 hom. )
Consequence
SLC6A1
NM_003042.4 missense
NM_003042.4 missense
Scores
2
17
Clinical Significance
Conservation
PhyloP100: 3.72
Genes affected
SLC6A1 (HGNC:11042): (solute carrier family 6 member 1) The protein encoded by this gene is a gamma-aminobutyric acid (GABA) transporter that localizes to the plasma membrane. The encoded protein removes GABA from the synaptic cleft, restoring it to presynaptic terminals. [provided by RefSeq, Jan 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), SLC6A1. . Gene score misZ 4.1766 (greater than the threshold 3.09). Trascript score misZ 4.9229 (greater than threshold 3.09). GenCC has associacion of gene with myoclonic-atonic epilepsy, myoclonic-astatic epilepsy.
BP4
Computational evidence support a benign effect (MetaRNN=0.109599024).
BP6
Variant 3-11017224-G-A is Benign according to our data. Variant chr3-11017224-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 2054325.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=2, Benign=1}.
BS2
High AC in GnomAd4 at 7 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC6A1 | NM_003042.4 | c.13G>A | p.Gly5Ser | missense_variant | 3/16 | ENST00000287766.10 | |
SLC6A1-AS1 | NR_046647.1 | n.105+1896C>T | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC6A1 | ENST00000287766.10 | c.13G>A | p.Gly5Ser | missense_variant | 3/16 | 1 | NM_003042.4 | P1 | |
SLC6A1-AS1 | ENST00000414969.2 | n.105+1896C>T | intron_variant, non_coding_transcript_variant | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000461 AC: 7AN: 151964Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
7
AN:
151964
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250678Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135686
GnomAD3 exomes
AF:
AC:
3
AN:
250678
Hom.:
AF XY:
AC XY:
2
AN XY:
135686
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1461650Hom.: 0 Cov.: 31 AF XY: 0.00000963 AC XY: 7AN XY: 727120
GnomAD4 exome
AF:
AC:
11
AN:
1461650
Hom.:
Cov.:
31
AF XY:
AC XY:
7
AN XY:
727120
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000461 AC: 7AN: 151964Hom.: 0 Cov.: 32 AF XY: 0.0000539 AC XY: 4AN XY: 74222
GnomAD4 genome
AF:
AC:
7
AN:
151964
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74222
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
2
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Myoclonic-atonic epilepsy Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 22, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 29, 2022 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 18, 2024 | The c.13G>A (p.G5S) alteration is located in exon 3 (coding exon 1) of the SLC6A1 gene. This alteration results from a G to A substitution at nucleotide position 13, causing the glycine (G) at amino acid position 5 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;.;T;.;T;T;.;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;T;.;.;.;D;D;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;N;.;N;.;N;N;.;.;.
MutationTaster
Benign
D;D
PrimateAI
Benign
T
PROVEAN
Benign
.;N;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.
REVEL
Benign
Sift
Benign
.;T;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.
Sift4G
Benign
.;T;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.
Polyphen
B;B;B;B;B;B;B;B;B;B;B;B;B;B;B;B;.;B;.;B;B;.;.;.
Vest4
0.16
MutPred
Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);Gain of phosphorylation at G5 (P = 0.049);
MVP
0.87
MPC
1.0
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at